// App-Quantinova.ai

P737 : The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable results

Researchers

Presenter

  • R Sagar

Principal Investigators

  • M Lenti

  • T Clark

  • H Rafferty

  • D Gracie

  • A Ford

  • A O'Connor

  • J Hamlin

  • T Ahmad

  • C Selinger

Medical Centers

  • St. James' University Hospital, Gastroenterology, Leeds, United Kingdom

  • Royal Devon & Exeter NHS Foundation Trust, Blood Sciences, Exeter, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Infectious Diseases (ID)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved